Neo Ivy Capital Management Reduces Stake in Halozyme Therapeutics

Biopharmaceutical firm sees institutional investor trim position by over 77%

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Neo Ivy Capital Management has reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 77.6% during the third quarter, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The firm now owns 5,386 shares of the biopharmaceutical company's stock, down from 24,073 shares previously.

Why it matters

Institutional investor activity can provide insights into market sentiment and potential shifts in a company's shareholder base. Halozyme Therapeutics is a prominent biopharmaceutical firm focused on drug delivery technologies, so changes in major investor positions may signal broader trends in the sector.

The details

According to the 13F filing, Neo Ivy Capital Management sold 18,687 shares of Halozyme Therapeutics during the third quarter, reducing its total position to 5,386 shares valued at $395,000. The firm did not provide a specific rationale for the stake reduction in the regulatory disclosure.

  • Neo Ivy Capital Management filed the 13F report disclosing the stake reduction on March 9, 2026.
  • The trades occurred during the third quarter of 2025.

The players

Neo Ivy Capital Management

An institutional investment firm that has reduced its position in Halozyme Therapeutics by over 77% as of the third quarter of 2025.

Halozyme Therapeutics, Inc.

A biopharmaceutical company headquartered in San Diego, California that specializes in the development and commercialization of drug delivery technologies.

Got photos? Submit your photos here. ›

The takeaway

The significant reduction in Neo Ivy Capital Management's stake in Halozyme Therapeutics could signal a shift in investor sentiment around the biopharmaceutical firm's prospects, though the specific reasons behind the trade are unclear from the limited disclosure. Ongoing monitoring of institutional investor activity and commentary will be important to assess the broader market view on Halozyme going forward.